NEW YORK – The Precede consortium and Konica Minolta Precision Medicine said Tuesday that KMPM and its subsidiaries, Ambry Genetics and Invicro, have partnered with the international effort to advance diagnostic and screening approaches for pancreatic cancer early detection.
Spread across 35 academic medical centers, Precede's goal is to increase the five-year survival rate for pancreatic cancer from 10 percent to 50 percent within the next 10 years, through advancement of early diagnostic and prevention strategies. The effort is currently enrolling eligible patients into its observational longitudinal prospective cohort study, with plans to eventually include over 100 institutional partners and over 10,000 high-risk individuals.
Under their new partnership, KMPM and Precede will combine resources in genetic testing, pathology, and imaging to identify individuals at elevated risk for developing pancreatic cancer, define that risk, and invite those at elevated risk into state-of-the art clinical screening programs.
Investigators intend to analyze and standardize data using KMPM's integrated diagnostics platform, Lattice, which runs on Amazon Web Services and uses Amazon HealthLake to store, transform, query, and analyze health data. The platform is expected to help shepherd the large amounts of genomic and other data generated under the consortium in order to derive new strategies for disease detection, prevention, and treatment.
"As a surgeon and scientist who has spent my entire career taking care of pancreatic cancer patients and trying to improve survival for this intractable disease, it is clear that early detection is likely to have the greatest impact in changing outcomes," Diane Simeone, director of the Pancreatic Cancer Center at NYU Langone Health and principal investigator of Precede, said in a statement. "Through this innovative partnership, we expect to curate and analyze large amounts of data in an unprecedented way to optimize early detection methods."